Vazegepant

As a highly disabling neurological disease worldwide, the demand for rapid antiemesis and analgesia during the acute attack of migraine has not been fully met for a long time, while the delayed antiemetic effect of oral ditan drugs has always been a clinical pain point. Zavegepant is a new generation of calcitonin gene-related peptide (CGRP) receptor antagonist. It inhibits neurogenic inflammation and pain signal transduction by highly selectively blocking the binding of CGRP to its receptor. Meanwhile, it has the formulation advantage of nasal spray administration, with higher bioavailability and faster onset of effect. It can not only be used for the treatment of acute migraine attacks in adults, but also has outstanding clinical applicability for patients accompanied by nausea and vomiting who are unable to take oral medications.

At present, the global market size of migraine treatment has exceeded 6 billion US dollars, CGRP-targeted drugs account for nearly 40%, and the compound annual growth rate remains above 18%. The original research product of zavegepant was approved for marketing by the FDA in 2020, and was introduced into the Chinese market in 2023. Currently, no generic drug has been approved in China, and only 3 enterprises have submitted marketing applications for the active pharmaceutical ingredient. The patent will expire in 2036, and the market space for generic and innovative drugs is considerable in the next 10 years.

CATO can provide a full set of impurity reference standards for zavegepant active pharmaceutical ingredient. All products meet the requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and are supported by structure confirmation reports and full set of traceability documents. All core specifications are in stock, which can meet the full-process needs of pharmaceutical enterprises from prescription research and development to registration and declaration.